Vandana Singh TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades' TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as ...

Local pharmaceutical giant AbbVie is suing drug manufacturer BeiGene over allegedly stealing trade secrets to develop a competing cancer drug following the hiring of a longtime AbbVie research ...

In a lawsuit filed Friday, lawyers for AbbVie argued that BeiGene “enticed and encouraged” former AbbVie scientist Huaqing Liu, who’s named as a defendant in the case, to jump ship and share ...

One of the world's top biopharma companies, AbbVie (NYSE: ABBV) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

Sept 9 (Reuters) - Pharmaceutical giant AbbVie (ABBV.N), opens new tab has sued cancer treatment maker BeiGene (6160.HK), opens new tab in Chicago federal court, accusing it of stealing trade ...

NORTH CHICAGO, Ill., Sept. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA ...

AbbVie has filed a lawsuit against BeiGene, alleging the biotechnology company of stealing trade secrets to develop a competing cancer therapy. The lawsuit, filed Sept. 6, alleges that former ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study. In the Phase 3 ...

AbbVie's nonprofit foundation is partnering with health care incubator Matter on a new accelerator to advance solutions to improve care for underserved communities. The AbbVie Foundation Health ...

AbbVie plans to present the full results at medical conferences and expects additional trial data from TEMPO-2 by the end of 2024. Tavapadon is an investigational D1/D5 dopamine receptor partial ...